Opko Health Inc. (OQ:OPK)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 4400 Biscayne Blvd
MIAMI FL 33137-3212
Tel: 1-212-8383777
Website: www.opko.com
IR: See website
<
Key People
Phillip Frost
Chairman of the Board, Chief Executive Officer
Jane H. Hsiao
Vice Chairman of the Board, Chief Technical Officer
Adam E. Logal
Chief Financial Officer, Senior Vice President
Jon Roger Cohen
Executive Chairman of BioReference Laboratories
Geoff Monk
President of BioReference
Steven D. Rubin
Executive Vice President - Administration, Director
Business Overview
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
Financial Overview
For the nine months ended 30 September 2018, Opko Health Inc. revenues decreased 5% to $768.4M. Net loss decreased 12% to $77M. Revenues reflect Diagnostics segment decrease of 40% to $427.4M, Pharmaceutical segment decrease of 28% to $81.8M, United States segment decrease of 14% to $646.5M, Israel segment decrease of 39% to $8.4M, Chile segment decrease of 3% to $32.6M. Lower net loss reflects Diagnostics segment loss decrease of 51% to $17.6M.
Employees: 6,030 as of Dec 31, 2017
Reporting Currency: U.S. Dollars
Enterprise value: $2,292M as of Sep 30, 2018
Annual revenue (TTM): $962.11M as of Sep 30, 2018
EBITDA (TTM): -$120.64M as of Sep 30, 2018
Net annual income (TTM): -$290.88M as of Sep 30, 2018
Free cash flow (TTM): -$111.66M as of Sep 30, 2018
Net Debt Last Fiscal Year: $165.03M as of Sep 30, 2018
Shares outstanding: 559,827,515 as of Nov 1, 2018
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization